ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2013
Clostridium difficile infection after adult autologous stem cell transplantation: a multicenter study of epidemiology and risk factors.
Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Prevalence ofFrontiers in cellular and infection microbiology · 2022Pooled it
- Acute abdomen in the immunocompromised patient: WSES, SIS-E, WSIS, AAST, and GAIS guidelines.World journal of emergency surgery : WJES · 2021Guideline
- A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Management ofEClinicalMedicine · 2025Review
- Epidemiology and Outcomes of RecurrentOpen forum infectious diseases · 2024Article
- Review
- Informing estimates of probability ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024Article
- The Role of Fecal Microbiota Transplantation in the Allogeneic Stem Cell Transplant Setting.Microorganisms · 2023Review
- Epidemiology of early infections and predictors of mortality after autologous hematopoietic stem-cell transplantation among multiple myeloma, Hodgkin, and non-Hodgkin lymphoma: the first experience from Palestine.BMC infectious diseases · 2022Article
- Association and risk factors of healthcare-associated infection and burden of illness among chemotherapy-induced ulcerative mucositis patients.Clinical oral investigations · 2022Article
- Humoral Immune Response toOpen forum infectious diseases · 2021Article
- Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients.Journal of clinical medicine · 2020Review
- A Single-Center Experience and Literature Review of Management Strategies forInfectious diseases in clinical practice (Baltimore, Md.) · 2020Article
- Article
- Risk forTransplantation direct · 2017Article
- Rates of Microbiologically Diagnosed Infection and Pathogen Detection in Hematopoietic Stem Cell Transplant Patients.Military medicine · 2016Article
- Risk factors for recurrent Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients.Bone marrow transplantation · 2016Article
- Article
- Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Article
- Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 6 institutions in 2 countries.
Funding
Abstract
We sought to describe the epidemiology of Clostridium difficile infection (CDI) among adult recipients of autologous hematopoietic stem cell transplantation (auto-HSCT) within the first year after HSCT in centers with variable epidemiology of hypertoxigenic strains. A multicenter, retrospective nested case-control study was conducted among 873 auto-HSCT recipients at Johns Hopkins Hospital (JHH) and Hôpital Maisonneuve-Rosemont (HMR) between January 2003 and December 2008. Despite center differences in the prevalence of NAP-1 strains during the study period (21% to 43% at JHH versus 80% to 84% in HMR), the 1-year incidence of CDI was similar in the 2 hospitals (6.2% at JHH versus 5.7% at HMR). The median time to infection was 11 days (interquartile range, 1 to 27 days). In case-control analyses, grade ≥2 mucositis (odds ratio [OR], 3.00; P = .02) and receipt of a fourth-generation cephalosporin (OR, 2.76; P = .04) were identified as predictors for CDI. Mucositis was the strongest predictor of risk for CDI in multivariate analysis (adjusted OR, 2.77; P = .03). CDI is a common and early complication of auto-HSCT. Treatment-related gastrointestinal mucosal damage, along with the potentially modifiable risk of antimicrobial exposure, influence the risk for CDI early after auto-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.